Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0324 | 0.2372 | 0.5 | |
Echinococcus multilocularis | dihydrofolate reductase | 0.0871 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0742 | 0.8197 | 0.7636 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0658 | 0.7019 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0658 | 0.7019 | 0.5 |
Schistosoma mansoni | dihydrofolate reductase | 0.0871 | 1 | 1 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0658 | 0.7019 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0658 | 0.7019 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0871 | 1 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0871 | 1 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.0871 | 1 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0658 | 0.7019 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0154 | 0 | 0.5 |
Echinococcus granulosus | tyrosine protein kinase shark | 0.0759 | 0.844 | 0.7954 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0324 | 0.2372 | 0.2372 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0871 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.0759 | 0.844 | 0.7954 |
Brugia malayi | thymidylate synthase | 0.0324 | 0.2372 | 0.2372 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0658 | 0.7019 | 0.5 |
Echinococcus granulosus | dihydrofolate reductase | 0.0871 | 1 | 1 |
Echinococcus multilocularis | tyrosine protein kinase shark | 0.0759 | 0.844 | 0.7954 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.0871 | 1 | 1 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0871 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.006 uM | inhibitory activity of compound against Multidrug resistant HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
IC50 (functional) | = 0.006 uM | inhibitory activity of compound against Multidrug resistant HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
IC50 (functional) | = 0.1 uM | inhibitory activity of compound against Multidrug resistance HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
IC50 (functional) | = 0.1 uM | inhibitory activity of compound against Multidrug resistance HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
IC50 (functional) | = 10 uM | Intrinsic cytotoxic activity of the compound against Multidrug resistant HCT116/VM46 cell line | ChEMBL. | 15546712 |
IC50 (functional) | = 10 uM | Intrinsic cytotoxic activity of the compound against Multidrug resistant HCT116/VM46 cell line | ChEMBL. | 15546712 |
IC50 (functional) | = 15 uM | Intrinsic cytotoxic activity of the compound against wild type HCT116 cell line | ChEMBL. | 15546712 |
IC50 (functional) | = 15 uM | Intrinsic cytotoxic activity of the compound against wild type HCT116 cell line | ChEMBL. | 15546712 |
Reversion (functional) | = 67 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
Reversion (functional) | = 67 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Vinblastine | ChEMBL. | 15546712 |
Reversion (functional) | = 100 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
Reversion (functional) | = 100 % | Multi drug resistance reversal in HCT116/VM46 cell line treated with Doxorubucin | ChEMBL. | 15546712 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 15546712 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.